Dartmouth-Hitchcock logo
Back
 
Medicine Grand Rounds - Cutaneous Toxicities from Targeted Anticancer Therapies

Dr. LeBoeuf describes an approach to evaluating cutaneous reactions to anticancer therapies that includes considering the patient’s specific drug regimen and patterns that give clues to causal culprits. The distribution (for example involvement of hands and feet, presence of mucosal lesions) and the type of lesions can be helpful in identifying both the medication causing the symptoms and the therapeutic interventions that are likely to provide relief. Effective management of these toxicities is essential for patient quality of life and in some cases enables patients to continue receiving potentially curative or life prolonging anticancer therapies. Oncologists should have a low threshold for seeking the advice of a skin toxicity program to provide specific and humane relief to cancer patients.

Activity Details

Start Date:  January 17, 2020
End Date:  January 17, 2022

You may claim CME credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Register for the learning activity by creating an account or logging in to your account.
  2. Click Continue to navigate to the Activity Material tab. Click View Presentation to view the recording. View the entire presentation.
  3. Return to this Activity page.
  4. Click Continue to navigate to the Evaluation tab; then click the Launch button to start the evaluation.
  5. Complete and Submit the evaluation and attestation form.

When the evaluation is submitted, you will be awarded credit. You may access your transcript for verification of participation at any time via Your Account. Need help? Visit the Support Page, send an Email, or call the Center for Learning and Professional Development at (603) 653-1234, Option 1.

Learning Outcome

Participants will be able to identify key reaction patterns associated with commonly used targeted anticancer therapies, develop initial management strategies for specific patterns of toxicity and identify when subspecialty referral or consultation would be beneficial.

Presenter
  • Nicole R. LeBoeuf, MD, MPH
    Assistant Professor of Dermatology, Harvard Medical School
    Clinical Director, The Center for Cutaneous Oncology
    Director, The Program in Skin Toxicities from Anticancer Therapies
    Dana-Farber/Brigham and Women’s Cancer Center

    About our presenter: 
    Dr. LeBoeuf completed her undergraduate training at Middlebury College, and received her medical degree from the University of Massachusetts Medical School in 2006.  She completed her residency in Dermatology at Columbia University, followed by a fellowship in Cutaneous Oncology at Brigham and Women’s/Dana-Farber Cancer Center at Harvard.

    Dr. LeBoeuf leads clinical trials in cutaneous lymphoma and rare skin malignancies as well as interventional studies for the prevention or management of side effects from cancer treatment.  Her research focuses on understanding the immunologic mechanisms of side effects to cancer therapeutics and implementing therapies or other interventions to mitigate them.
Accreditation

Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Requirements for Successful Completion

In order to receive credit for this Continuing Medical Education (CME) activity, you must:

  • View the entire presentation
  • Complete the online Attestation of Attendance & Evaluation Form (you must register to access).
Disclosure

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Cutaneous Toxicities from Targeted Anticancer Therapies (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. All potential conflict(s) were resolved.


* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio. 

* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and is on the Scientific Advisory Board for Allurion. 


Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center
clpd.support@hitchcock.org


Type:     Internet Activity (Enduring Material)
15 Registered Users

0